Mechanism of action and clinical development of ticagrelor, a novel platelet ADP P2Y12 receptor antagonist

Expert Review of Cardiovascular Therapy
Davide CapodannoDominick J Angiolillo

Abstract

Inhibition of the platelet ADP P2Y(12) receptor has shown to be associated with a marked risk reduction of atherothrombotic events in high-risk settings, including patients with acute coronary syndromes and those undergoing percutaneous coronary interventions. Clinical and laboratory experiences have led to a better comprehension of the drawbacks of currently available P2Y(12) receptor antagonists, stimulating the development of novel agents. Ticagrelor (AZD6140) is the first drug of a new chemical class called cyclopentyltriazolopyrimidine, which is administered orally and has a reversible P2Y(12) receptor inhibitory effect. Preclinical and early-phase clinical studies have shown ticagrelor to be characterized by a rapid, greater and consistent antiplatelet effect with a favorable safety profile. Recent findings from large-scale Phase III trials showed ticagrelor to be more effective in preventing ischemic events in acute coronary syndrome patients without an increased risk of protocol-defined major bleeding, but with an increase in the rate of nonprocedure-related bleeding, compared with currently recommended treatment regimens. This article provides an overview of the pharmacologic properties and clinical development of tica...Continue Reading

References

Jun 1, 1995·Trends in Pharmacological Sciences·R G HumphriesP Leff
Feb 2, 1999·Journal of Medicinal Chemistry·A H IngallW Tomlinson
Aug 25, 2001·The New England Journal of Medicine·S YusufUNKNOWN Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators
Aug 25, 2001·Lancet·S R MehtaUNKNOWN Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators
Nov 19, 2002·JAMA : the Journal of the American Medical Association·Steven R SteinhublUNKNOWN CREDO Investigators. Clopidogrel for the Reduction of Events During Observation
Mar 11, 2005·The New England Journal of Medicine·Marc S SabatineUNKNOWN CLARITY-TIMI 28 Investigators
Apr 27, 2005·Seminars in Thrombosis and Hemostasis·J J J van Giezen, Robert G Humphries
Sep 7, 2005·JAMA : the Journal of the American Medical Association·Marc S SabatineUNKNOWN Clopidogrel as Adjunctive Reperfusion Therapy (CLARITY)-Thrombolysis in Myocardial Infarction (TIMI) 28 Investigators
Nov 8, 2005·Lancet·Z M ChenUNKNOWN COMMIT (ClOpidogrel and Metoprolol in Myocardial Infarction Trial) collaborative group
Apr 10, 2007·Journal of the American College of Cardiology·Dominick J AngiolilloMarco A Costa
Dec 14, 2007·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·Dominick J Angiolillo
Jul 31, 2008·American Heart Journal·Dominick J Angiolillo, Piera Capranzano
Jul 31, 2008·American Heart Journal·Dominick J Angiolillo, Luis A Guzman
Feb 14, 2009·The American Journal of Cardiology·Dominick J AngiolilloLisa K Jennings
Jun 26, 2009·Journal of Thrombosis and Haemostasis : JTH·J J J VAN GiezenP J Greasley
Jul 3, 2009·Thrombosis and Haemostasis·José Luis Ferreiro, Dominick J Angiolillo
Jul 17, 2009·Cardiovascular Therapeutics·Steen Husted, J J J van Giezen
Sep 1, 2009·The New England Journal of Medicine·Lars WallentinMona Thorsén
Sep 10, 2009·Circulation·Andrew S Wechsler, J Yasha Kresh
Oct 15, 2009·European Heart Journal·Jean-Pierre BassandUNKNOWN OASIS 5 and OASIS 6 Investigators

❮ Previous
Next ❯

Citations

Feb 14, 2013·Journal of Cardiovascular Translational Research·Fabiana RolliniDominick J Angiolillo
Jul 27, 2010·American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions·David Vivas, Dominick J Angiolillo
Jul 9, 2010·Future Cardiology·Masafumi UenoDominick J Angiolillo
Jun 2, 2011·Future Cardiology·Antonio Tello-MontoliuDominick J Angiolillo
Mar 24, 2011·Journal of Atherosclerosis and Thrombosis·Masafumi UenoDominick Joseph Angiolillo
Jun 19, 2013·International Journal of Applied & Basic Medical Research·Divya Goel
Aug 9, 2012·Future Cardiology·Fabiana RolliniDominick J Angiolillo
Jun 19, 2013·Journal of Neurointerventional Surgery·Ricardo A HanelWilliam D Freeman
Feb 1, 2014·Medicina clínica·Antonio Tello-MontoliuMariano Valdés
Mar 9, 2013·Expert Review of Cardiovascular Therapy·Piera Capranzano, Davide Capodanno
Jan 21, 2011·Expert Opinion on Pharmacotherapy·Davide CapodannoGeorge Dangas
Feb 13, 2016·Journal of the American College of Cardiology·Dominick J AngiolilloRoxana Mehran
Apr 26, 2012·European Journal of Medicinal Chemistry·Guocheng LiuHongguang Du
May 15, 2012·Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions·Shahdad Azmoon, Dominick J Angiolillo
May 25, 2012·Journal of Cardiac Surgery·Harold L Lazar
Jul 17, 2013·Journal of Thrombosis and Haemostasis : JTH·D CapodannoD J Angiolillo
Sep 24, 2015·Trends in Cardiovascular Medicine·Yongwhi ParkDominick J Angiolillo
Jan 5, 2011·Journal of the American College of Cardiology·David J Schneider
Jan 7, 2015·Annual Review of Pharmacology and Toxicology·Jeremiah P Depta, Deepak L Bhatt
Aug 5, 2016·Nature Reviews. Cardiology·Davide CapodannoDominick J Angiolillo
May 4, 2016·Journal of Clinical Gastroenterology·Elizabeth E BollingerDaniel L Raines
Nov 12, 2013·Journal of Cardiovascular Pharmacology and Therapeutics·Judy W M Cheng
Oct 6, 2010·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·José Luis FerreiroDominick J Angiolillo
Mar 24, 2017·Thrombosis and Haemostasis·Fabiana RolliniDominick J Angiolillo
May 19, 2017·The Journal of Immunology : Official Journal of the American Association of Immunologists·Chaoyan QinChangsheng Du
Oct 19, 2012·Current Opinion in Cardiology·Jeremiah P Depta, Deepak L Bhatt
Jul 12, 2017·Expert Review of Clinical Pharmacology·Jae Youn MoonDominick J Angiolillo
Sep 14, 2011·Nature Reviews. Cardiology·Arun KalyanasundaramUNKNOWN Medscape
Feb 6, 2019·Evidence-based Complementary and Alternative Medicine : ECAM·Kyungho Kim, Kwang-Il Park
May 13, 2020·Expert Opinion on Investigational Drugs·Rocco P MilluzzoDominick J Angiolillo
May 18, 2021·Expert Review of Clinical Pharmacology·Mattia GalliDominick J Angiolillo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.